| Literature DB >> 12039561 |
Jacques Dumas1, Holia Hatoum-Mokdad, Robert N Sibley, Roger A Smith, William J Scott, Uday Khire, Wendy Lee, Jill Wood, Donald Wolanin, Jeffrey Cooley, Donald Bankston, Aniko M Redman, Robert Schoenleber, Yolanda Caringal, David Gunn, Romulo Romero, Martin Osterhout, Holger Paulsen, Timothy J Housley, Scott M Wilhelm, John Pirro, Du-Shieng Chien, Gerald E Ranges, Alka Shrikhande, Andrew Muzsi, Elizabeth Bortolon, Jean Wakefield, Cynthia Gianpaolo Ostravage, Ajay Bhargava, Thuy Chau.
Abstract
Inhibitors of the MAP kinase p38 provide a novel approach for the treatment of osteoporosis, inflammatory disorders, and cancer. We have identified N-(3-tert-butyl-1-methyl-5-pyrazolyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea as a potent and selective p38 kinase inhibitor in biochemical and cellular assays. This compound is orally active in two acute models of cytokine release (TNF-induced IL-6 and LPS-induced TNF) and a chronic model of arthritis (20-day murine collagen-induced arthritis).Entities:
Mesh：
Substances：
Year: 2002 PMID： 12039561 DOI： 10.1016/s0960-894x(02)00238-x
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823